ProMIS Neurosciences, Inc. Annual report pursuant to Section 13 and 15(d)

NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)

NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	4,084,375	3,466,453
Options issued and outstanding under stock option plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	1,043,025	738,037
Warrants.
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	1,873,622	1,560,688
Convertible debt.
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive		1,166,667
Series 1 Convertible Preferred Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	1,166,667
Deferred share units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	1,061	1,061